Grants and Contracts Details
Description
The proposed work aims to develop and refine a new generation of aureolic acid type natural product
analogues with significantly diminished toxicity that will be useful as anticancer drugs and/or as drugs to treat
neurological diseases, arthritis and hematologic disorders. To enable the production of these fine-tuned drugs
through combinatorial biosynthesis or chemo-enzymatic engineering, in-depth research of the biosynthetic
machinery of three aureolic acid pathways will be explored, including key enzymes, followed by enzyme reengineering.
In addition, based on so far achieved structure-activity-relationship studies, chemoenzymatic
approaches for drug derivatization, glycosylation exchange methods and chemoenzymatic glycorandomization
techniques will be applied to selectively alter crucial structural features.
Status | Finished |
---|---|
Effective start/end date | 6/1/01 → 6/30/20 |
Funding
- National Cancer Institute: $554,661.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.